Yatsen Holding Ltd (YSG) Stock Analysis and Metrics

Yatsen Holding

NYSE: YSG

$3.34 ▲ +0.04 (+1.21%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap6.15 Bn

P/E-547.02

P/S10.18

Div. Yield0.00

ROIC (Qtr)-0.01

Total Debt (Qtr)3.00 Mn

Revenue Growth (1y) (Qtr)25.36

Add ratio to table…

About

Yatsen Holding Limited is a leading China based beauty group that develops manufactures and sells color cosmetics and skincare products. Founded in 2016 the company has built a portfolio of brands including Perfect Diary Little Ondine Pink Bear Galénic DR. WU Eve Lom and EANTiM. Its mission is to create an exciting new journey of beauty discovery for consumers worldwide.

Yatsen Holding Limited generates revenue primarily from the sale of its color cosmetics and skincare products. The company sells through online channels such as major e commerce platforms social media platforms and its own official accounts as well as through offline experience stores located in shopping malls across China. Revenue is derived from the retail sales value of products sold under its various brands.

The company operates through the following segments: Color Cosmetics Brands and Skincare Brands.

• The Color Cosmetics Brands segment includes Perfect Diary Little Ondine and Pink Bear and offers a broad range of lip eye and face products targeting mass to mid end consumers. Perfect Diary is the flagship brand providing high quality innovative color cosmetics with designs that appeal to Gen Z and millennials. Little Ondine focuses on trend setting functional makeup such as liquid contour and eyebrow liners while Pink Bear emphasizes high value for money lip gloss products for teenage and young adult customers.

• The Skincare Brands segment comprises Galénic DR. WU mainland China business Eve Lom and EANTiM and offers premium skincare and haircare products. Galénic provides high end dermo cosmetics with scientific formulas derived from plant extracts. DR. WU focuses on dermatologist grade solutions for acne related skin problems using mandelic acid. Eve Lom delivers luxury skincare with natural ingredients that cleanse hydrate tone and exfoliate the skin. EANTiM develops microbiome focused skincare and haircare products aimed at improving skin health.

Yatsen Holding Limited holds a leading position in China's beauty industry with its flagship brand Perfect Diary ranked among the top color cosmetics brands by retail sales value. The company competes with multinational players such as L'Oréal and Estée Lauder as well as domestic brands including Florasphere and Herborist. Competitive advantages stem from its direct to consumer digital marketing strategy a strong network of key opinion leaders frequent intellectual property collaborations robust research and development capabilities and an efficient supply chain supported by a joint venture manufacturing hub.

Yatsen Holding Limited serves primarily Gen Z and millennial consumers located in tier one and tier two cities across China. The company also attracts international customers for its premium skincare brands Galénic and Eve Lom. Its customer base engages through online platforms social media and offline experience stores.

Investment Thesis

▲ Bull case

Yatsen Holding’s Q1 FY26 results reveal a structural shift toward higher-margin skincare, with skin care brands revenue surging 58.5% year over year and driving overall revenue growth of 22.5%, while gross margin expanded to a record 80.2% from 79.1%, indicating improving product mix and pricing power. This trend is reinforced by management’s focus on portfolio expansion around proven hero products like Galénic’s anti-aging cream and Dr. Wu’s dermatology research initiatives, which are creating differentiated, science-backed offerings that command premium pricing and foster customer loyalty in a crowded market. The company’s strategic pivot away from declining color cosmetics (down 5% year over year) toward high-growth, high-margin skincare is not merely a tactical adjustment but a fundamental realignment of its business model toward sustainable profitability, a shift the market may be underestimating as it focuses on headline operating losses.
Despite rising operating expenses to 89.9% of net revenues, Yatsen is making deliberate, high-return investments in R&D and brand equity that are laying the groundwork for future operating leverage, with R&D spending increasing to 3.9% of revenues and yielding tangible innovation pipelines such as Galénic’s anti-aging cream, Dr. Wu’s acne research fund, and the white paper on Chinese dermatological research — all of which enhance brand authority and long-term pricing power. The company’s explicit commitment to leveraging AI and data tools to improve consumer insights, content production, and marketing efficiency — mentioned in response to competitive pressures — represents an underappreciated catalyst that could significantly reduce customer acquisition costs over time, especially as these systems scale and optimize channel mix, as evidenced by the Otitis brand’s successful B2T channel strategy being extrapolated to other brands.
The completion of the private placement of convertible notes and warrants with new institutional investor participation as of May 21, 2026, signals strong confidence from sophisticated capital in Yatsen’s multi-brand strategy and long-term vision, providing not only non-dilutive funding flexibility but also validation of its ability to execute on strategic initiatives like portfolio expansion and channel optimization, which are critical to reversing the current operating loss trend; this financing event, coupled with $934.2 million in cash reserves, gives the company ample runway to sustain investment in growth engines without immediate pressure to cut R&D or marketing spend, allowing it to pursue a path to profitability that prioritizes sustainable scale over short-term margin compression.

Yatsen Holding’s Q1 FY26 results reveal a structural shift toward higher-margin skincare, with skin care brands revenue surging 58.5% year over year and driving overall revenue growth of 22.5%, while gross margin expanded to a record 80.2% from 79.1%, indicating improving product mix and pricing power. This trend is reinforced by management’s focus on portfolio expansion around proven hero products like Galénic’s anti-aging cream and Dr. Wu’s dermatology research initiatives, which are creating differentiated, science-backed offerings that command premium pricing and foster customer loyalty in a crowded market. The company’s strategic pivot away from declining color cosmetics (down 5% year over year) toward high-growth, high-margin skincare is not merely a tactical adjustment but a fundamental realignment of its business model toward sustainable profitability, a shift the market may be underestimating as it focuses on headline operating losses.
Despite rising operating expenses to 89.9% of net revenues, Yatsen is making deliberate, high-return investments in R&D and brand equity that are laying the groundwork for future operating leverage, with R&D spending increasing to 3.9% of revenues and yielding tangible innovation pipelines such as Galénic’s anti-aging cream, Dr. Wu’s acne research fund, and the white paper on Chinese dermatological research — all of which enhance brand authority and long-term pricing power. The company’s explicit commitment to leveraging AI and data tools to improve consumer insights, content production, and marketing efficiency — mentioned in response to competitive pressures — represents an underappreciated catalyst that could significantly reduce customer acquisition costs over time, especially as these systems scale and optimize channel mix, as evidenced by the Otitis brand’s successful B2T channel strategy being extrapolated to other brands.
The completion of the private placement of convertible notes and warrants with new institutional investor participation as of May 21, 2026, signals strong confidence from sophisticated capital in Yatsen’s multi-brand strategy and long-term vision, providing not only non-dilutive funding flexibility but also validation of its ability to execute on strategic initiatives like portfolio expansion and channel optimization, which are critical to reversing the current operating loss trend; this financing event, coupled with $934.2 million in cash reserves, gives the company ample runway to sustain investment in growth engines without immediate pressure to cut R&D or marketing spend, allowing it to pursue a path to profitability that prioritizes sustainable scale over short-term margin compression.

▼ Bear case

Yatsen Holding’s operating expenses grew at 32.5% year over year, outpacing revenue growth of 22.5% and pushing operating expense ratio to 89.9% of net revenues — up from 83.2% — primarily due to relentless increases in selling and marketing expenses (now 72.2% of revenues) driven by rising traffic acquisition costs and brand-building efforts, a trend management acknowledged as a systemic industry headwind rather than a temporary inefficiency, suggesting that the company may be trapped in a costly customer acquisition cycle where incremental revenue requires disproportionate marketing spend, undermining the path to profitability despite top-line growth.
The company’s net loss widened to $61.9 million (6.1% margin) from $5.6 million (0.7% margin) year over year, with non-GAAP net loss reversing prior-year income, and net cash used in operating activities turning negative at $90 million from prior-year inflow of $23.8 million, indicating that the business model is currently consuming cash rather than generating it, a deterioration that management attributed to “core brands, coupled with higher traffic acquisition costs,” signaling that even as skincare brands grow, the underlying economics of customer acquisition are becoming increasingly unfavorable, a structural risk that could persist if digital advertising costs continue to rise faster than consumer lifetime value improvements.
While management highlights innovation and brand equity as growth drivers, the R&D increase to 3.9% of revenues remains relatively low in absolute terms ($39.4 million) and may not be sufficient to create defensible moats against intense competition in the premium skincare segment, especially as foreign brands continue to encroach on the high-end market — a threat management acknowledged as “very intense” without detailing concrete barriers to entry or pricing power advantages beyond vague references to “global heritage” and “AI tools,” leaving investors exposed to the risk that Yatsen’s differentiation is more aspirational than operational, and that its current growth is being fueled by unsustainable marketing spend rather than organic, brand-led demand that could withstand a pullback in promotional activity.

Yatsen Holding’s operating expenses grew at 32.5% year over year, outpacing revenue growth of 22.5% and pushing operating expense ratio to 89.9% of net revenues — up from 83.2% — primarily due to relentless increases in selling and marketing expenses (now 72.2% of revenues) driven by rising traffic acquisition costs and brand-building efforts, a trend management acknowledged as a systemic industry headwind rather than a temporary inefficiency, suggesting that the company may be trapped in a costly customer acquisition cycle where incremental revenue requires disproportionate marketing spend, undermining the path to profitability despite top-line growth.
The company’s net loss widened to $61.9 million (6.1% margin) from $5.6 million (0.7% margin) year over year, with non-GAAP net loss reversing prior-year income, and net cash used in operating activities turning negative at $90 million from prior-year inflow of $23.8 million, indicating that the business model is currently consuming cash rather than generating it, a deterioration that management attributed to “core brands, coupled with higher traffic acquisition costs,” signaling that even as skincare brands grow, the underlying economics of customer acquisition are becoming increasingly unfavorable, a structural risk that could persist if digital advertising costs continue to rise faster than consumer lifetime value improvements.
While management highlights innovation and brand equity as growth drivers, the R&D increase to 3.9% of revenues remains relatively low in absolute terms ($39.4 million) and may not be sufficient to create defensible moats against intense competition in the premium skincare segment, especially as foreign brands continue to encroach on the high-end market — a threat management acknowledged as “very intense” without detailing concrete barriers to entry or pricing power advantages beyond vague references to “global heritage” and “AI tools,” leaving investors exposed to the risk that Yatsen’s differentiation is more aspirational than operational, and that its current growth is being fueled by unsustainable marketing spend rather than organic, brand-led demand that could withstand a pullback in promotional activity.

Peer Comparison

Companies in the Household & Personal Products

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PG	PROCTER & GAMBLE Co	341.94 Bn	20.49	3.94	37.03 Bn
2	UL	Unilever Plc	131.50 Bn	27.72	3.97	32.92 Bn
3	CL	Colgate Palmolive Co	72.27 Bn	32.63	3.48	7.94 Bn
4	KVUE	Kenvue Inc.	36.23 Bn	22.34	2.37	8.66 Bn
5	KMB	Kimberly Clark Corp	35.62 Bn	89.49	2.15	7.08 Bn
6	EL	Estee Lauder Companies Inc	28.99 Bn	-151.78	1.95	7.31 Bn
7	CHD	Church & Dwight Co Inc /De/	22.75 Bn	24.31	407.73	2.40 Bn
8	CLX	Clorox Co /De/	12.26 Bn	14.78	1.81	2.49 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password